RxDoctor Payments Data

Paula Reis, DO

Internal Medicine · Foxborough, MANPI 1730116229

Payments from drug & device makers

$293in general payments, 2019–2025

Across 14 payments — averaging $20.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$98
  • AbbVie$47
  • Amgen$36
  • AstraZeneca$23
  • Microtransponder, Inc.$20
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$15
  • plus $54 from 4 others

What the payments were for

  • Food & beverage$293100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott1$98
AbbVie(2 entities)3$47
Amgen2$36
AstraZeneca2$23
Microtransponder, Inc.1$20
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC1$15
Sanofi-aventis U.S. LLC1$14
Medtronic1$14
GSK1$14
Boehringer Ingelheim1$11

How this compares

$293 in reported general payments places this provider in the 70th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$128,327
Medicare patients
288
Services billed
1,165

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide51$58,849
EliquisApixaban39$40,504
XareltoRivaroxaban26$38,935
TrulicityDulaglutide18$23,900
MounjaroTirzepatide20$21,152
JardianceEmpagliflozin23$18,763
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$12,668
Atorvastatin Calcium430$5,500
Rosuvastatin Calcium180$4,996
Albuterol Sulfate HfaAlbuterol Sulfate55$2,431
Omeprazole149$2,078
Valsartan52$2,065
Losartan Potassium201$1,977
Ezetimibe53$1,945
Levothyroxine Sodium245$1,849

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$11$18,76323 claims
GSKAnoro Ellipta$14$12,66820 claims
AbbVieSynthroid$47$1,62324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Foxborough

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →